Compare APWC & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APWC | FLNA |
|---|---|---|
| Founded | 1996 | 1998 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.3M | 61.8M |
| IPO Year | 1997 | 2000 |
| Metric | APWC | FLNA |
|---|---|---|
| Price | $1.25 | $0.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 2.1K | ★ 702.8K |
| Earning Date | 08-14-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,119,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.25 | $0.64 |
| 52 Week High | $2.28 | $2.03 |
| Indicator | APWC | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 36.42 | 34.93 |
| Support Level | N/A | N/A |
| Resistance Level | $1.39 | $1.05 |
| Average True Range (ATR) | 0.02 | 0.04 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 3.74 |
Asia Pacific Wire & Cable Corp Ltd is a holding company. It is principally engaged in the manufacture and distribution of enameled wire, power cable, and telecommunications products in Thailand, Singapore, Australia, the PRC, Hong Kong, and certain other markets in the Asia Pacific region. It also provides project engineering services in the supply, delivery, and installation of power cables (SDI). Some of the company's products are Bare wires, Power cables, Communication cables, Electronic wires & cables, and Enamelled wires. The company's geographical segments are North Asia, Thailand, and the rest of the World.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.